Aflibercept

Generic Name: Aflibercept

Brand Names: Eylea, Zaltrap, Yesafili

Drug Type: Biotech

Chemical Formula: -

CAS Number: 862111-32-8

Unique Ingredient Identifier: 15C2VL427D

Background: Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15%...

Indication: The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
...

Associated Conditions: Branch Retinal Vein Occlusion With Macular Edema, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Macular Edema With Central Retinal Vein Occlusions, Metastatic Colorectal Cancer (CRC), Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD), Retinopathy of Prematurity (ROP)

Associated Therapies: -

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

Phase 3

Recruiting

Conditions: Wet Age-related Macular Degeneration

Interventions: Drug: Tarcocimab tedromer
Drug: Tabirafusp tedromer
Drug: Aflibercept

First Posted Date: 2024-08-16

Last Posted Date: 2024-10-29

Lead Sponsor: Kodiak Sciences Inc

Target Recruit Count: 675

Registration Number: NCT06556368

Locations: 🇺🇸
California Retina Consultants, Oxnard, California, United States
🇺🇸
Retina Consultants of Southern Colorado, Colorado Springs, Colorado, United States
🇺🇸
National Ophthalmic Research Institute, Fort Myers, Florida, United States

and more 31 locations

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

Phase 3

Recruiting

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: OTX-TKI
Drug: Aflibercept

First Posted Date: 2024-07-11

Last Posted Date: 2024-07-24

Lead Sponsor: Ocular Therapeutix, Inc.

Target Recruit Count: 825

Registration Number: NCT06495918

Locations: 🇺🇸
Retina Vitreous Associates of Florida- Saint Petersburg, Saint Petersburg, Florida, United States
🇺🇸
Erie Retina Research, Erie, Pennsylvania, United States
🇺🇸
Sierra Eye Associates, Reno, Nevada, United States

and more 2 locations

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Phase 3

Recruiting

Conditions: Neovascular Age-Related Macular Degeneration

Interventions: Drug: OTX-TKI (axitinib implant)
Drug: Aflibercept

First Posted Date: 2024-01-25

Last Posted Date: 2024-07-05

Lead Sponsor: Ocular Therapeutix, Inc.

Target Recruit Count: 300

Registration Number: NCT06223958

Locations: 🇺🇸
Atlantis Eyecare, Huntington Beach, California, United States
🇺🇸
CA RCMG Retinal Consultants Medical Group, Inc., Modesto, California, United States
🇺🇸
AzulVision, Pasadena, California, United States

and more 53 locations

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Phase 2

Recruiting

Conditions: Metastatic Uveal Melanoma

Interventions: Drug: ZIV-Aflibercept
Drug: Cemiplimab

First Posted Date: 2023-11-07

Last Posted Date: 2024-11-08

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 32

Registration Number: NCT06121180

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

Phase 2

Recruiting

Conditions: Retinal Degeneration
Edema
Diabetic Macular Edema
Macular Edema
Diabetic Retinopathy
Eye Diseases
Retinal Disease
Diabetes Mellitus
Retinal Diseases

Interventions: Drug: Aflibercept
Drug: foselutoclax

First Posted Date: 2023-08-25

Last Posted Date: 2024-05-07

Lead Sponsor: Unity Biotechnology, Inc.

Target Recruit Count: 50

Registration Number: NCT06011798

Locations: 🇺🇸
California Retina Consultants, Bakersfield, California, United States
🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸
Salehi Retina Institute Inc., Huntington Beach, California, United States

and more 16 locations

Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial

Phase 4

Recruiting

Conditions: Pars Plana Vitrectomy
Intraoperative Optical Coherence Tomography
Diabetic Macular Edema
Dexamethasone Intravitreal Implant

Interventions: Drug: Ozurdex
Drug: Aflibercept

First Posted Date: 2023-08-14

Last Posted Date: 2024-03-06

Lead Sponsor: Tianjin Medical University Eye Hospital

Target Recruit Count: 64

Registration Number: NCT05990829

Locations: 🇨🇳
Tianjin medical university eye hosipital, Tianjin, Tianjin, China

Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

Phase 2

Active, not recruiting

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: CLS-AX
Drug: Aflibercept

First Posted Date: 2023-06-07

Last Posted Date: 2023-11-02

Lead Sponsor: Clearside Biomedical, Inc.

Target Recruit Count: 60

Registration Number: NCT05891548

Locations: 🇺🇸
Retina Group of Florida, Fort Lauderdale, Florida, United States
🇺🇸
Southeast Retina Center, Augusta, Georgia, United States
🇺🇸
Western Carolina Retinal Associates P.A., Asheville, North Carolina, United States

and more 29 locations

Efficacy and Safety of RC28-E Versus Aflibercept

Phase 3

Recruiting

Conditions: Wet Age-related Macular Degeneration

Interventions: Drug: RC28-E
Drug: Aflibercept

First Posted Date: 2023-02-14

Last Posted Date: 2023-08-31

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 432

Registration Number: NCT05727397

Locations: 🇨🇳
Beijing Hospital, Beijing, Beijing, China

Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E

Phase 4

Completed

Conditions: Age-Related Macular Degeneration

Interventions: Drug: Brolucizumab
Drug: Aflibercept

First Posted Date: 2023-02-02

Last Posted Date: 2024-05-08

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 30

Registration Number: NCT05710471

Locations: 🇭🇰
Grantham Hospital, Hong Kong, Hong Kong

A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

Phase 3

Completed

Conditions: Chorioretinal Vascular Disease

Interventions: Drug: ABP 938
Drug: Aflibercept

First Posted Date: 2023-01-30

Last Posted Date: 2024-11-27

Lead Sponsor: Amgen

Target Recruit Count: 49

Registration Number: NCT05704725

Locations: 🇺🇸
Retina Consultants of Texas - Bellaire Retina Center, Bellaire, Texas, United States
🇺🇸
Retinal Consultants of Texas - San Antonio Retina Center, San Antonio, Texas, United States
🇺🇸
Retina Consultants of Texas - Austin Retina, Austin, Texas, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy